<?xml version="1.0" encoding="UTF-8"?>
<p id="Par4">According to the World Health Organization (WHO), there is no existing data from randomized clinical trials to advocate any specific anti-nCoV therapy for patients either suspected or diagnosed with SARS-CoV-2. Unlicensed treatments can only be given in the circumstance of ethically approved clinical trials or under the Monitored Emergency Use of Unregistered Interventions System (MEURI), with strict supervision (World Health Organization 
 <xref ref-type="bibr" rid="CR61">2020a</xref>). However, researchers have tested a number of FDA-approved drugs against SARS-CoV-2 infection, and these drugs have shown promising antiviral activity in both cell culture and animal models. Some of these drugs are also in clinical trial for SARS-CoV-2 (Li and De Clercq 
 <xref ref-type="bibr" rid="CR33">2020</xref>). In the past 2Â months, drugs from various classes such as nucleoside analogs, protease inhibitors, and host-targeted agents have been tested to discover an authorized antiviral agent against SARS-CoV-2 infection (Table 
 <xref rid="Tab2" ref-type="table">10.2</xref>). The National Medical Products Administration of China has recently approved fapilavir as the first antiviral medication for the treatment of SARS-CoV-2.
</p>
